glucagon


( Last Updated : March 17, 2020)
Generic Name:
glucagon
Project Status:
Complete
Therapeutic Area:
Severe hypoglycemic reactions
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Baqsimi
Project Line:
Reimbursement Review
Project Number:
SR0626-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details

Manufacturer Requested Reimbursement Criteria1:
For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Severe hypoglycemic reactions
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2
Call for patient input posted June 25, 2019
Patient group input closed August 15, 2019
Clarification:

- Patient input submission received from Diabetes Canada and Type 1 Together/Ensemble
Patient input summary sent for review to patient input groups September 12, 2019
Patient group comments on input summary closed September 19, 2019
Clarification:

- Patient input summary feedback received
Submission received July 24, 2019
Submission accepted August 08, 2019
Review initiated August 09, 2019
Draft CADTH review report(s) sent to sponsor October 24, 2019
Comments from sponsor on draft CADTH review report(s) received November 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsor November 29, 2019
Canadian Drug Expert Committee (CDEC) meeting December 11, 2019
CDEC recommendation sent to sponsor and drug plans December 24, 2019
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans January 22, 2020
CDEC Final Recommendation posted January 24, 2020
Redaction requests from sponsor on draft CADTH review report(s) received February 05, 2020
Redacted CADTH review report(s) sent to sponsor and drug plans February 18, 2020
Validation of redacted CADTH review report(s) received February 25, 2020
Final CADTH review report(s) posted March 09, 2020

Files

Recommendation and Reasons

Clinical Report

Pharmacoeconomic Report

Patient Group Input Submissions